Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMLX 
Amylyx Pharmaceuticals Inc (AMLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/16/2024: AMLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -45.97% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/16/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 295.93M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 1208054 | Beta -0.51 | 52 Weeks Range 1.57 - 7.27 | Updated Date 04/2/2025 |
52 Weeks Range 1.57 - 7.27 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.43 |
Earnings Date
Report Date 2025-03-04 | When - | Estimate -0.59 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) 6113.38% |
Management Effectiveness
Return on Assets (TTM) -51.31% | Return on Equity (TTM) -100.88% |
Valuation
Trailing PE - | Forward PE 2.77 | Enterprise Value 121412243 | Price to Sales(TTM) 3.39 |
Enterprise Value 121412243 | Price to Sales(TTM) 3.39 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA -11.71 | Shares Outstanding 88602496 | Shares Floating 59471749 |
Shares Outstanding 88602496 | Shares Floating 59471749 | ||
Percent Insiders 11.7 | Percent Institutions 65.66 |
Analyst Ratings
Rating 3.83 | Target Price 8 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amylyx Pharmaceuticals Inc
Company Overview
History and Background
Amylyx Pharmaceuticals Inc. was founded in 2013 by Justin Klee and Joshua Cohen. The company focuses on developing new treatments for neurodegenerative diseases. A significant milestone was the FDA approval of Relyvrio for ALS in 2022.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Development and commercialization of treatments for neurodegenerative diseases, primarily focusing on Amyotrophic Lateral Sclerosis (ALS).
Leadership and Structure
The leadership team includes Joshua Cohen (Co-CEO), Justin Klee (Co-CEO), and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to research and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Relyvrio: Relyvrio (sodium phenylbutyrate and taurursodiol) is Amylyx's first approved product for the treatment of ALS. Market share data is still evolving, but it is considered a significant entrant in the ALS treatment landscape. Competitors include Mitsubishi Tanabe Pharma with Radicava and generic riluzole.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the neurodegenerative disease therapeutics market, is characterized by high unmet needs, intense competition, and significant regulatory hurdles. There's a growing demand for effective treatments for diseases like ALS.
Positioning
Amylyx positions itself as a leader in developing novel treatments for neurodegenerative diseases. Its competitive advantage stems from its focus on modulating multiple pathways involved in neuronal cell death and dysfunction.
Total Addressable Market (TAM)
The estimated TAM for ALS therapeutics is substantial, potentially exceeding several billion dollars annually. Amylyx, with Relyvrio, is positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Relyvrio)
- Novel therapeutic approach
- Strong research and development capabilities
- Experienced management team
Weaknesses
- Limited product portfolio (reliance on Relyvrio)
- Relatively small company size compared to established pharmaceutical giants
- Ongoing debate regarding the efficacy of Relyvrio
Opportunities
- Expansion of Relyvrio's label to other neurodegenerative diseases
- Development of new therapeutic candidates in the pipeline
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
Threats
- Competition from existing and emerging ALS treatments
- Regulatory hurdles and potential delays in approval processes
- Negative clinical trial results for pipeline candidates
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MTPC.F
- BMY
Competitive Landscape
Amylyx's advantage lies in its novel mechanism of action for Relyvrio. Disadvantages include its smaller size and limited product portfolio compared to larger pharmaceutical companies like Mitsubishi Tanabe Pharma and Bristol Myers Squibb.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Amylyx's historical growth is marked by its successful development and approval of Relyvrio. Pre-approval, growth was primarily focused on R&D. Post-approval, it centers on commercialization and market penetration.
Future Projections: Future growth projections are highly dependent on Relyvrio's market uptake and the success of pipeline development. Analyst estimates vary widely due to the uncertainties surrounding the ALS market and the ongoing debate about Relyvrio's efficacy.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Relyvrio, conducting post-marketing studies to further validate its efficacy, and advancing other therapeutic candidates in the pipeline.
Summary
Amylyx is a relatively new player in the neurodegenerative disease space with a focus on ALS treatment. The company's success hinges on the market acceptance of Relyvrio, their only approved product. Future growth depends on successful pipeline development and strategic partnerships. They are susceptible to competition due to their small size compared to established pharmaceutical companies.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
HALO
Halozyme Therapeutics Inc
HALO
Halozyme Therapeutics Inc
SRPT
Sarepta Therapeutics Inc
SRPT
Sarepta Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market conditions are dynamic and will change the state of the company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amylyx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-01-07 | Co-Founder, Co-CEO & Director Mr. Joshua B. Cohen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://amylyx.com |
Full time employees 123 | Website https://amylyx.com | ||
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.